Sollis Therapeutics is an emerging clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics.
Sollis’ first product is an extended-release non-opioid, non-steroid analgesic and anti-inflammatory drug placed into the lumbar epidural space to treat sciatica, a severely painful condition affecting ~5% of adults annually.
Sollis Therapeutics is a privately-held, emerging specialty pharmaceutical company with a pivotal stage product in development and several candidate programs under evaluation.
